An interesting NEDD4-1 substrate in this regard is the receptor tyrosine (and serine) kinase RET (abbreviation for rearranged during transfection), the canonical receptor for the TGF-β (transforming growth factor-β)-related neurotrophic factor family member GDNF (glial cell line-derived neurotrophic factor), which is currently in clinical trials in PD patients [245,250,251,252] (see Figure 1). Here, NEDD4 is linked to Parkinson disease.